Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)

NCT01947907 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.

NCT NCT01947907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01947907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)
Lead sponsor
Ascendis Pharma A/S
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
September 30, 2015
Enrollment
53 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency (ghd)